Cargando…
Metformin inhibits hepatocellular glucose, lipid and cholesterol biosynthetic pathways by transcriptionally suppressing steroid receptor coactivator 2 (SRC-2)
The ability of the anti-diabetic drug metformin to inhibit anabolic processes including gluconeogenesis and lipogenesis is partly attributable to activation of the AMP-activated protein kinase (AMPK) pathway. The p160 steroid receptor coactivator 2 (SRC-2) is a key regulator of cellular metabolism a...
Autores principales: | Madsen, Andre, Bozickovic, Olivera, Bjune, Jan-Inge, Mellgren, Gunnar, Sagen, Jørn V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4637908/ https://www.ncbi.nlm.nih.gov/pubmed/26548416 http://dx.doi.org/10.1038/srep16430 |
Ejemplares similares
-
Downregulation of Steroid Receptor Coactivator-2 Modulates Estrogen-Responsive Genes and Stimulates Proliferation of MCF-7 Breast Cancer Cells
por: Fenne, Ingvild S., et al.
Publicado: (2013) -
Maternal PCOS status and metformin in pregnancy: Steroid hormones in 5–10 years old children from the PregMet randomized controlled study
por: Hanem, Liv Guro Engen, et al.
Publicado: (2021) -
SRC-3, a Steroid Receptor Coactivator: Implication in Cancer
por: Li, Licen, et al.
Publicado: (2021) -
Steroid receptor coactivators, HER-2 and HER-3 expression is stimulated by tamoxifen treatment in DMBA-induced breast cancer
por: Moi, Line L Haugan, et al.
Publicado: (2012) -
COL6A3 expression in adipose tissue cells is associated with levels of the homeobox transcription factor PRRX1
por: Dankel, Simon N., et al.
Publicado: (2020)